Cortria makes appointments
This article was originally published in Scrip
Cortria, a clinical-stage pharmaceutical company backed by the venture capital firms Domain Associates and MVM Life Sciences, has named Daniel Grau CEO and vice-chairman and Richard King director. Mr Grau was formerly chief operating officer at CombinatoRx; Mr King is president and chief operating officer at Tercica and was previously executive vice-president of commercial operations at Kos Pharmaceuticals. Cortria's first product candidate, TRIA-662, is in Phase II clinical development for the treatment of dyslipidaemia.